Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center in Houston, Texas; Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute in Durham, North Carolina; and Bradley R. Corr, MD, of University of Colorado Cancer Center in Aurora, Colorado, discuss how antibody-drug conjugates are changing the treatment of endometrial and ovarian cancers, including biomarker testing, where these agents fit after immunotherapy, new folate receptor alpha, HER2, TROP2, B7-H4, and CDH6 data, side effect management, and sequencing, filmed at the 2026 European Society for Medical Oncology Congress.
Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center, opens a discussion on antibody-drug conjugates (ADCs) in endometrial cancer with Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, and Bradley R. Corr, MD, of University of Colorado Cancer Center.
Bradley R. Corr, MD, of University of Colorado Cancer Center, and Angeles Alvarez Secord, MD, MHSc, of Duke Cancer Institute, describe how they test patients with endometrial cancer for biomarkers, in conversation with moderator Shannon N. Westin, MD, MPH, FACOG, FASCO, of The University of Texas MD Anderson Cancer Center.
